Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
Diagnostics · 11.08.2023 · 13 (16) · 2649
DOI: 10.3390/diagnostics13162649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 11.08.2023. Verfasst von Inki Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science ICT and Future Planning, Ministry of Science and ICT of the Republic of Korea.
Abstract (Originalsprache)
Background
This study compared the effects of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as 64Cu-chelating agents in newly developed prostate-specific membrane antigen (PSMA) target compounds, 64Cu-cudotadipep and 64Cu-cunotadipep, on pharmacokinetics.
Methods
The in vitro stability of the chelators was evaluated using human and mouse serum. In vitro PSMA-binding affinity and cell uptake were compared using human 22Rv1 cells. To evaluate specific PSMA-expressing tumor-targeting efficiency, micro-positron emission tomography (mcroPET)/computed tomography (CT) and biodistribution analysis were performed using PSMA+ PC3-PIP and PSMA− PC3-flu tumor xenografts.
Results
The serum stability of DOTA- or NOTA-conjugated 64Cu-cudotadipep and 64Cu-cunotadipep was >97%. The Ki value of the NOTA derivative, cunotadipep, in the in vitro affinity binding analysis was higher (2.17 ± 0.25 nM) than that of the DOTA derivative, cudotadipep (6.75 ± 0.42 nM). The cunotadipep exhibited a higher cellular uptake (6.02 ± 0.05%/1 × 106 cells) compared with the cudotadipep (2.93 ± 0.06%/1 × 106 cells). In the biodistribution analysis and microPET/CT imaging, the 64Cu-labeled NOTA derivative, 64Cu-cunotadipep, demonstrated a greater tumor uptake and lower liver uptake than the DOTA derivative.
Conclusions
This study indicates that the PSMA-targeted 64Cu-cunotadipep can be applied in clinical practice owing to its high diagnostic power for prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
- Research Institute of Radiopharmaceuticals, FutureChem Co., Ltd., Seoul 04793, Republic of Korea.
- Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
- Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Förderung
- Ministry of Science ICT and Future Planning
- Ministry of Science and ICT of the Republic of Korea
Zitieren
APA
Lee, I., Kim, M. H., Lee, K., Oh, K., Lim, H., Ahn, J. H., Lee, Y. J., Cheon, G. J., Chi, D. Y., & Lim, S. M. (2023). Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer. Diagnostics, 13(16), 2649. https://doi.org/10.3390/diagnostics13162649
Vancouver
Lee I, Kim MH, Lee K, Oh K, Lim H, Ahn JH, et al. Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer. Diagnostics. 2023;13(16):2649. doi:10.3390/diagnostics13162649
BibTeX
@article{Lee2023,
author = {Lee, Inki and Kim, Min Hwan and Lee, Kyongkyu and Oh, Keumrok and Lim, Hyunwoo and Ahn, Jae Hun and Lee, Yong Jin and Cheon, Gi Jeong and Chi, Dae Yoon and Lim, Sang Moo},
title = {Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {16},
pages = {2649},
doi = {10.3390/diagnostics13162649}
}
EUVIMED